Tashkent, Uzbekistan (UzDaily.com) -- The Chinese company Anhui Zhifei Longcom Biopharmaceutical on Monday released the results of a small study on its coronavirus vaccine (ZF-UZ-VAC2001). This drug can cause antibodies against the omicron variant, although the reaction is weaker than against the original variant of the virus, Reuters reported.

The company said neutralizing antibodies against omicron were found in samples from 78% of 32 subjects who had received three vaccinations a month earlier.

Of the 32 people, 16 received the second and third doses more than four months apart, and they all had neutralizing antibodies to the omicron, but their antibody levels were about three-fold lower than those observed against the parent coronavirus.